Adenomyosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN027 MIFTS: 61	Adenomyosis Categories: Muscle diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis ⁵⁷ ¹² ⁷⁶ ⁵³ ⁴⁴ ¹⁵

Endometriosis of Uterus ¹² ¹⁵ ⁷³

Endometriosis of Myometrium ¹²

Endometriosis, Myometrium ¹²

Endometriosis Interna ¹²

Uterine Adenomyosis ¹²

Characteristics:

OMIM:

⁵⁷

Inheritance:
autosomal vs. x-linked dominant

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases Muscle diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the genitourinary system

Noninflammatory disorders of female genital tract

Endometriosis

Endometriosis of uterus

External Ids:

OMIM ⁵⁷ 600458

Disease Ontology ¹² DOID:288

ICD10 ³³ N80.0

ICD9CM ³⁵ 617.0

MeSH ⁴⁴ D062788

NCIt ⁵⁰ C6996

SNOMED-CT ⁶⁸ 76376003

MedGen ⁴² C0341858

SNOMED-CT via HPO ⁶⁹ 287085006 42030000 248250000 more

UMLS ⁷³ C0341858

Sources

Summaries for Adenomyosis

NIH Rare Diseases : ⁵³ Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and endometriosis. An important gene associated with Adenomyosis is OXTR (Oxytocin Receptor), and among its related pathways/superpathways are GPCR Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Ketorolac and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and endothelial, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : ¹² A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : ⁵⁷ Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : ⁷⁶ Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Sources

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)

#	Related Disease	Score	Top Affiliating Genes
1	uterine anomalies	31.5	CDH1 CYP19A1 ESR1 PGR VEGFA
2	endometriosis	30.5	CYP19A1 ESR1 GNRH1 HOXA10 PGR PTGS2
3	endometrial adenocarcinoma	30.4	ESR1 HOXA10 PGR VEGFA
4	myoma	30.3	CYP19A1 ESR1 GNRH1 HOXA10 PGR
5	leiomyoma	30.2	CYP19A1 ESR1 GNRH1 MME PGR
6	adenosarcoma	30.2	ESR1 MME PGR
7	endometrial stromal sarcoma	30.0	CYP19A1 ESR1 MME PGR
8	endometriosis of ovary	29.9	CYP19A1 ESR1 HOXA10 PGR
9	leiomyomatosis	29.8	ESR1 GNRH1 PGR
10	intravenous leiomyomatosis	29.8	ESR1 MME
11	cystitis	29.8	NGF PTGS2 TRPV1
12	breast fibroadenoma	29.5	CYP19A1 ESR1 MME PGR
13	endometrial cancer	28.9	CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MME
14	breast cancer	28.7	CDH1 CYP19A1 ESR1 GNRH1 MMP2 MMP9
15	adenocarcinoma	10.6
16	infertility	10.4
17	light chain deposition disease	10.3	MMP2 MMP9
18	female reproductive endometrioid cancer	10.3	ESR1 PGR
19	synchronous bilateral breast carcinoma	10.3	ESR1 PGR
20	adamantinous craniopharyngioma	10.3	MMP9 VEGFA
21	vestibular gland benign neoplasm	10.3	ESR1 PGR
22	bartholin's gland adenoma	10.3	ESR1 PGR
23	fungal keratitis	10.3	MMP9 TIMP2
24	vulvar syringoma	10.3	ESR1 PGR
25	extracranial arteriovenous malformation	10.3	MMP2 MMP9
26	glassy cell carcinoma of the cervix	10.3	ESR1 PGR
27	tuberculum sellae meningioma	10.3	PGR PRL
28	lung leiomyoma	10.3	ESR1 PGR
29	focal myositis	10.3	MMP2 MMP9
30	vulvar benign neoplasm	10.3	ESR1 PGR
31	trigonitis	10.3	ESR1 PGR
32	balanitis xerotica obliterans	10.3	PTGS2 VEGFA
33	vulvar leiomyoma	10.3	ESR1 PGR
34	villous adenocarcinoma	10.3	MMP2 MMP9
35	spastic entropion	10.3	MMP2 MMP9
36	extrapelvic endometriosis	10.3
37	lentigo maligna melanoma	10.3	MMP2 MMP9
38	predominantly cortical thymoma	10.3	ESR1 PGR
39	adenomyoma	10.3
40	breast medullary carcinoma	10.3	ESR1 PGR
41	angiokeratoma circumscriptum	10.3	MMP9 VEGFA
42	breast scirrhous carcinoma	10.3	ESR1 PGR
43	bartholin's gland benign neoplasm	10.3	ESR1 PGR
44	oncocytic breast carcinoma	10.2	ESR1 PGR
45	acute transverse myelitis	10.2	MMP2 MMP9
46	intracystic papillary adenoma	10.2	PGR PRL
47	senile ectropion	10.2	MMP2 MMP9
48	progesterone resistance	10.2	ESR1 PGR
49	ischemic colitis	10.2	MMP2 MMP9 VEGFA
50	gingival hypertrophy	10.2	MMP9 TIMP2

Graphical network of the top 20 diseases related to Adenomyosis:

Sources

Symptoms & Phenotypes for Adenomyosis

Symptoms via clinical synopsis from OMIM:

⁵⁷

Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

Human phenotypes related to Adenomyosis:

³²

#	Description	HPO Source Accession
1	abnormal bleeding ³²	HP:0001892
2	dysmenorrhea ³²	HP:0100607
3	abnormality of the genitourinary system ³²	HP:0000119

MGI Mouse Phenotypes related to Adenomyosis:

⁴⁶ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.36	CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
2	behavior/neurological	MP:0005386	10.32	CYP19A1 ESR1 MMP9 NGF OXTR PGR
3	cardiovascular system	MP:0005385	10.31	CDH1 CYP19A1 ESR1 MMP2 MMP9 NGF
4	growth/size/body region	MP:0005378	10.31	CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP2
5	immune system	MP:0005387	10.31	CDH1 CYP19A1 ESR1 GNRH1 MME MMP2
6	integument	MP:0010771	10.29	CDH1 CYP19A1 ESR1 GNRH1 MME MMP9
7	endocrine/exocrine gland	MP:0005379	10.25	CDH1 CYP19A1 ESR1 GNRH1 HOXA10 OXTR
8	hematopoietic system	MP:0005397	10.18	CYP19A1 ESR1 GNRH1 MMP2 MMP9 PGR
9	nervous system	MP:0003631	10.18	CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9
10	digestive/alimentary	MP:0005381	10.16	CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
11	neoplasm	MP:0002006	10.1	CDH1 ESR1 GNRH1 MMP2 MMP9 PGR
12	muscle	MP:0005369	10.09	CYP19A1 ESR1 MMP2 MMP9 NGF OXTR
13	liver/biliary system	MP:0005370	10.06	CYP19A1 ESR1 GNRH1 MME PRL PTGS2
14	normal	MP:0002873	10	CDH1 CYP19A1 ESR1 GNRH1 MMP2 NGF
15	no phenotypic analysis	MP:0003012	9.92	CDH1 ESR1 NGF OXTR PGR PTGS2
16	renal/urinary system	MP:0005367	9.7	CYP19A1 ESR1 GNRH1 MMP9 PTGS2 TRPV1
17	reproductive system	MP:0005389	9.7	CDH1 CYP19A1 ESR1 GNRH1 HOXA10 MMP9
18	skeleton	MP:0005390	9.28	CYP19A1 ESR1 GNRH1 HOXA10 MMP2 MMP9

Sources

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ketorolac

Approved

Phase 4

66635-83-4, 74103-06-3

3826

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Acetaminophen

Approved

Phase 4

103-90-2

1983

Dienogest

Approved

Phase 4

65928-58-7

Nandrolone phenpropionate

Approved, Illicit, Investigational

Phase 4

62-90-8

229455

Nandrolone decanoate

Approved, Illicit

Phase 4

360-70-3

9677

Nandrolone

Experimental, Investigational

Phase 4

434-22-0

9904

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Contraceptives, Oral

Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Hormones

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Contraceptive Agents

Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable

Contraceptives, Oral, Combined

Phase 4,Phase 2,Early Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Analgesics, Non-Narcotic

Phase 4

Antirheumatic Agents

Phase 4

Anti-Inflammatory Agents

Phase 4,Not Applicable

Analgesics

Phase 4,Phase 3

Cyclooxygenase Inhibitors

Phase 4

Antipyretics

Phase 4

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 3,Not Applicable

Contraceptive Agents, Male

Phase 4

Androgens

Phase 4

Anabolic Agents

Phase 4

Letrozole

Approved, Investigational

Phase 2, Phase 3

112809-51-5

3902

Goserelin

Approved

Phase 2, Phase 3

65807-02-5

47725 5311128

Progesterone

Approved, Vet_approved

Phase 2, Phase 3

57-83-0

5994

Mifepristone

Approved, Investigational

Phase 2, Phase 3

84371-65-3

55245

Ramosetron

Investigational

Phase 3

132036-88-5

Lactitol

Investigational

Phase 2, Phase 3

585-86-4

3871

Neurotransmitter Agents

Phase 3,Phase 1

Serotonin Agents

Phase 3

Serotonin Antagonists

Phase 3

Gastrointestinal Agents

Phase 3,Not Applicable

Autonomic Agents

Phase 3,Not Applicable

Antiemetics

Phase 3,Not Applicable

Estrogens

Phase 2, Phase 3,Early Phase 1,Not Applicable

Estrogen Antagonists

Phase 2, Phase 3

Aromatase Inhibitors

Phase 2, Phase 3

Estrogen Receptor Antagonists

Phase 2, Phase 3

Steroid Synthesis Inhibitors

Phase 2, Phase 3

Contraceptives, Postcoital

Phase 2, Phase 3

Luteolytic Agents

Phase 2, Phase 3

Micronutrients

Phase 3

Trace Elements

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

Levonorgestrel

Approved, Investigational

Phase 2,Early Phase 1,Not Applicable

17489-40-6, 797-63-7

13109

Lidocaine

Approved, Vet_approved

Phase 2

137-58-6

3676

Ropivacaine

Approved

Phase 2

84057-95-4

175805 71273

Interventional clinical trials:

(show top 50) (show all 63)

#	Name	Status	NCT ID	Phase	Drugs
1	Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure	Completed	NCT02227316	Phase 4	IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2	Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis	Not yet recruiting	NCT03654144	Phase 4	Dienogest;Combined Oral Contraceptive
3	Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis	Withdrawn	NCT03325868	Phase 4	Ulipristal Acetate
4	Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy	Unknown status	NCT01483417	Phase 3
5	The Use of Doppler to Diagnose Myometrial Masses	Unknown status	NCT01833871	Phase 2, Phase 3
6	Single-port Access Laparoscopic-assisted Vaginal Hysterectomy	Unknown status	NCT01048931	Phase 3
7	Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy	Unknown status	NCT02011659	Phase 3	Ramosetron
8	Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis	Completed	NCT01218581	Phase 2, Phase 3	received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
9	Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy	Completed	NCT01064128	Phase 3
10	Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis	Recruiting	NCT03520439	Phase 2, Phase 3	Mifepristone;Placebo
11	Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study	Active, not recruiting	NCT02437175	Phase 3
12	Adenomyosis and Ulipristal Acetate	Unknown status	NCT02587000	Phase 2	Ulipristal acetate;Placebo
13	LNG-IUS for Treatment of Dysmenorrhea	Completed	NCT01601366	Phase 2	Combined oral contraceptives
14	Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding	Completed	NCT02248194	Phase 2
15	Superior Hypogastric Nerve Block for Pain Control Post-UFE	Completed	NCT02270255	Phase 2	0.75% Ropivacaine;1% Xylocaine
16	Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis	Not yet recruiting	NCT03749109	Phase 2	Quinagolide 1080 µg;Placebo
17	Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis	Withdrawn	NCT02794467	Phase 2	Epelsiban;Placebo
18	Vaginal Bromocriptine for Treatment of Adenomyosis	Completed	NCT01821001	Phase 1	Vaginal Bromocriptine
19	Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri	Unknown status	NCT03037944	Early Phase 1	Yasmin
20	Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis	Unknown status	NCT01259180	Not Applicable
21	Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis	Unknown status	NCT00172588
22	Proliferation of Endometrial Stromal Cells in Adenomyosis	Unknown status	NCT00173212
23	Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)	Unknown status	NCT02556411	Not Applicable	LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
24	Health-Related QoL Among Women Receiving Hysterectomy in NTUH	Unknown status	NCT00155870
25	Progestin Treatment for Endometrial Stromal Cells in Adenomyosis	Unknown status	NCT00155051
26	To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy	Unknown status	NCT01564602	Not Applicable
27	Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy	Unknown status	NCT02086344	Not Applicable
28	Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis	Unknown status	NCT03006406	Not Applicable	Long term GnRH-a (3.75mg)
29	The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH)	Unknown status	NCT00928044
30	Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy	Unknown status	NCT01289314	Not Applicable
31	Histopathological Diagnosis of Adenomyosis	Completed	NCT02340533	Not Applicable
32	Norwegian Adenomyosis Study I	Completed	NCT02201719
33	Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis	Completed	NCT03027648	Not Applicable
34	Levonorgestrel Intrauterine System and Adenomyosis	Completed	NCT03104309	Not Applicable
35	Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis	Completed	NCT03778359		Leuprorelin;Dienogest;Progestins
36	New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma	Completed	NCT02997787
37	What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography	Completed	NCT01992718	Early Phase 1
38	Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis	Completed	NCT03586063
39	Use of Dexamethasone in Uterine Artery Embolization	Completed	NCT02056717	Not Applicable	Dexamethasone;Normal saline
40	Uterine Artery Embolization for Symptomatic Fibroids	Completed	NCT00354471
41	Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?	Completed	NCT02192606	Not Applicable
42	Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy	Completed	NCT01806012	Not Applicable
43	AMH Levels Change During Treatment With GnRh Agonist	Completed	NCT02086279	Not Applicable	GnRH analogue
44	Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility	Completed	NCT02108665	Not Applicable
45	Surgical Success After Laparoscopic vs Abdominal Hysterectomy	Completed	NCT01793584	Not Applicable
46	Electronic Catheter Stethoscope	Completed	NCT01463462
47	Effect of Salpingectomy During Conservative Hysterectomy	Completed	NCT01628432	Not Applicable
48	Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility	Completed	NCT02399501	Not Applicable
49	The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms	Recruiting	NCT02495311
50	A Multi-omics Study of Adenomyosis	Recruiting	NCT03742843

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Sources

Genetic Tests for Adenomyosis

Sources

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

⁴¹

Uterus, Pituitary, Endothelial, Breast, Bone, Lung, Ovary

Sources

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 1051)

#	Title	Authors	Year
1	Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )	Bruun M.R....Ramlau-Hansen C.H.	2018
2	Clinical Usefulness of the Microbubble Contrast Agent SonoVue in Enhancing the Effects of High-Intensity Focused Ultrasound for the Treatment of Adenomyosis. ( 29689636 )	Jingqi W....Kun Z.	2018
3	Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )	Rocha T.P....AbrALo M.S.	2018
4	Adenomyosis and urinary system symptoms. ( 29655132 )	Aydin G.A....Yavuz A.	2018
5	ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )	Zhou W....Zhang Y.	2018
6	The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. ( 29736395 )	Li J.J....Duan H.	2018
7	Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )	Tskhay V....D9ikailly G.	2018
8	Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review. ( 29305234 )	Tan J....Bedaiwy M.A.	2018
9	Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? ( 29893860 )	Guo S.W....Groothuis P.G.	2018
10	The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. ( 29040186 )	ErkilinAs S....Sanci M.	2018
11	Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. ( 29962279 )	Groothuis P.G....Guo S.W.	2018
12	The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )	Shin Y.J....Han Y.J.	2018
13	Effects of pelvic endometriosis and adenomyosis on ciliary beat frequency and muscular contractions in the human fallopian tube. ( 29753325 )	Xia W....Zhang J.	2018
14	Adenomyosis and Endometrial Cancer: Literature Review. ( 29874641 )	Habiba M....Benagiano G.	2018
15	GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. ( 29922037 )	Guo S....Feng Y.	2018
16	The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )	Kim S.Y....Kim J.H.	2018
17	Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )	Ou K.Y....Chuang L.	2018
18	Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )	Liu X....Guo S.W.	2018
19	The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. ( 29871559 )	Cai X....Nie J.	2018
20	A sonographic classification and reporting system for diagnosing adenomyosis. ( 29790217 )	Van den Bosch T....Huirne J.A.F.	2018
21	Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )	Hou Y....Huang X.	2018
22	Evaluation of NovaSure<sup>Ar</sup> global endometrial ablation in symptomatic adenomyosis: A longitudinal study with a 36 month follow-up. ( 29886317 )	Philip C.A....Dubernard G.	2018
23	Anterior Focal Adenomyosis and Bladder Deep Infiltrative: is There a Link? ( 29432902 )		2018
24	Accuracy and Reproducibility of Sonoelastography for the Assessment of Fibroids and Adenomyosis, with Magnetic Resonance Imaging as Reference Standard. ( 29784438 )		2018
25	A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )		2018
26	Endophytic-Type Endometrial Cancer with Adenomyosis Successfully Diagnosed with Hysteroscopic Endometrial Biopsy Using an 8.3-mm Operative Resectoscope: A Case Report. ( 29928209 )		2018
27	Uterine adenomyosis and adenomyoma: the surgical approach. ( 29566853 )		2018
28	Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )		2018
29	Long-term dienogest administration in patients with symptomatic adenomyosis. ( 29845696 )		2018
30	Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. ( 29699636 )		2018
31	Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )		2018
32	Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: Imply the possible treatment of adenomyosis. ( 29752208 )		2018
33	Associations between a single nucleotide polymorphism of stress-induced phosphoprotein 1 and endometriosis/adenomyosis. ( 29673672 )		2018
34	Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution. ( 29845687 )		2018
35	Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )		2018
36	Introduction: Uterine adenomyosis, another enigmatic disease of our time. ( 29526476 )	Donnez J...Dolmans MM	2018
37	Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. ( 29552942 )	Li Q...Hua KQ	2018
38	News on Adenomyosis. ( 29554861 )	Maduro MR	2018
39	Minimally invasive treatment of adenomyosis. ( 29555380 )	Dueholm M	2018
40	Pathogenesis of uterine adenomyosis: invagination or metaplasia? ( 29566849 )	Garc?a-Solares J...Dolmans MM	2018
41	Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. ( 29566850 )	Gordts S...Campo R	2018
42	Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. ( 29566851 )	Bazot M...Dara? E	2018
43	Role of medical therapy in the management of uterine adenomyosis. ( 29566852 )	Vannuccini S...Petraglia F	2018
44	Association of Endometriosis and Adenomyosis: Vast Literature but Scant Conclusive Data. ( 29581073 )	Koninckx PR...Gomel V	2018
45	Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis. ( 29998482 )	Ota K...Mizunuma H	2018
46	Menstruation-related disseminated intravascular coagulation in an adenomyosis patient: case report and review of the literature. ( 30044152 )	Cernogoraz A...Ricci G	2018
47	Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations. ( 30063420 )	Dueholm M...Aagaard J	2018
48	Current facts constituting an understanding of the nature of adenomyosis. ( 30085434 )	Aleksandrovych V...Gil K	2018
49	Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. ( 30087549 )	Ecker AM...Donnellan NM	2018
50	Coexistence of adenomyosis, adenocarcinoma, endometrial and myometrial lesions in resected uterine specimens. ( 30101029 )	Tetikkurt S...Usta AT	2018

Sources

Genes for Adenomyosis

Genes related to Adenomyosis (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	OXTR	Oxytocin Receptor	Protein Coding	23.06	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	PGR	Progesterone Receptor	Protein Coding	23.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR1	Estrogen Receptor 1	Protein Coding	22.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	22.36	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
5	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	22.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	MMP2	Matrix Metallopeptidase 2	Protein Coding	21.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	GNRH1	Gonadotropin Releasing Hormone 1	Protein Coding	21.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	21.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MME	Membrane Metalloendopeptidase	Protein Coding	21.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	NGF	Nerve Growth Factor	Protein Coding	21.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CDH1	Cadherin 1	Protein Coding	21.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PRL	Prolactin	Protein Coding	21.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	HOXA10	Homeobox A10	Protein Coding	21.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	MMP9	Matrix Metallopeptidase 9	Protein Coding	20.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	20.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	20.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Adenomyosis

Sources

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Sources

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.57	ESR1 GNRH1 MMP2 MMP9 NGF PTGS2
2	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.13	CDH1 ESR1 GNRH1 NGF TIMP2 VEGFA
3	Circadian entrainment ³⁷ Show member pathways Cholinergic synapse ³⁷ Dopaminergic synapse ³⁷ Estrogen signaling pathway ³⁷ Glutamatergic synapse ³⁷ Relaxin receptors ⁶⁶ Relaxin signaling pathway ³⁷ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁵	12.9	ESR1 MMP2 MMP9 PGR VEGFA
4	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.64	CDH1 ESR1 MMP2 MMP9 VEGFA
5	Pathways in cancer ³⁷	12.6	CDH1 ESR1 MMP2 MMP9 PTGS2 VEGFA
6	Development Endothelin-1/EDNRA signaling ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA transactivation of EGFR ²² GnRH signaling pathway ³⁷ Inflammatory mediator regulation of TRP channels ³⁷	12.52	GNRH1 MMP2 NGF TRPV1 VEGFA
7	Proteoglycans in cancer ³⁷	12.15	ESR1 MMP2 MMP9 VEGFA
8	Integrated Breast Cancer Pathway ¹	11.98	CDH1 CYP19A1 ESR1 VEGFA
9	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.94	CDH1 GNRH1 NGF TIMP2
10	Adhesion ⁴	11.88	CDH1 MMP2 MMP9
11	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.82	ESR1 PGR PRL
12	Interleukin-4 and 13 signaling ⁶⁶	11.81	MMP2 MMP9 PTGS2 VEGFA
13	Matrix Metalloproteinases ¹ Show member pathways Activation of Matrix Metalloproteinases ⁶⁶ Inhibition of Matrix Metalloproteinases ⁶⁴	11.76	MMP2 MMP9 TIMP2
14	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.66	CDH1 MMP2 MMP9
15	Cell adhesion_ECM remodeling ²²	11.53	MMP2 MMP9 TIMP2
16	Angiogenesis (CST) ⁴	11.51	MMP2 MMP9 PTGS2 TIMP2
17	Celecoxib Pathway, Pharmacodynamics ⁶¹	11.5	MMP9 PTGS2 VEGFA
18	Aryl Hydrocarbon Receptor ¹	11.38	ESR1 PTGS2 VEGFA
19	Bladder cancer ³⁷ ¹	11.32	CDH1 MMP2 MMP9 VEGFA
20	Colorectal Cancer Metastasis ⁶⁴	11.24	CDH1 MMP2 MMP9 PTGS2 VEGFA
21	A-beta Pathways: Uptake and Degradation ⁶⁵	11.16	MME MMP2 MMP9
22	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.06	MMP2 MMP9 PTGS2 VEGFA
23	Plasma membrane estrogen receptor signaling ¹	11.02	ESR1 MMP2 MMP9
24	Angiogenesis (WikiPathways) ¹	10.92	MMP9 TIMP2 VEGFA
25	A-beta Pathways: Plaque Formation and APP Metabolism ⁶⁵	10.86	MME MMP2 MMP9
26	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶¹	10.11	CYP19A1 ESR1

Sources

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.7	GNRH1 MMP2 MMP9 NGF PRL TIMP2
2	extracellular region	GO:0005576	9.56	CDH1 GNRH1 MMP2 MMP9 NGF PRL
3	extracellular matrix	GO:0031012	8.92	MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	9.95	GNRH1 MMP9 NGF PTGS2 VEGFA
2	positive regulation of apoptotic process	GO:0043065	9.91	MMP9 NGF PTGS2 TRPV1
3	cytokine-mediated signaling pathway	GO:0019221	9.86	MMP2 MMP9 PTGS2 VEGFA
4	female pregnancy	GO:0007565	9.75	GNRH1 OXTR PRL
5	response to organic substance	GO:0010033	9.74	CDH1 PTGS2 TIMP2
6	memory	GO:0007613	9.7	NGF OXTR PTGS2
7	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043154	9.69	NGF PTGS2 VEGFA
8	extracellular matrix disassembly	GO:0022617	9.67	MMP2 MMP9 TIMP2
9	response to cytokine	GO:0034097	9.65	OXTR PTGS2 TIMP2
10	response to peptide hormone	GO:0043434	9.63	GNRH1 OXTR TRPV1
11	cellular response to ATP	GO:0071318	9.62	PTGS2 TRPV1
12	androgen metabolic process	GO:0008209	9.61	CYP19A1 ESR1
13	sensory perception of pain	GO:0019233	9.61	MME PTGS2 TRPV1
14	macrophage differentiation	GO:0030225	9.6	MMP9 VEGFA
15	mammary gland alveolus development	GO:0060749	9.59	ESR1 VEGFA
16	estrous cycle	GO:0044849	9.58	GNRH1 OXTR
17	lactation	GO:0007595	9.58	OXTR PRL VEGFA
18	response to organic cyclic compound	GO:0014070	9.56	GNRH1 OXTR PRL PTGS2
19	response to drug	GO:0042493	9.55	CDH1 OXTR PRL PTGS2 TIMP2
20	ovulation cycle	GO:0042698	9.54	GNRH1 PRL
21	embryo implantation	GO:0007566	9.54	MMP2 MMP9 PTGS2
22	mammary gland development	GO:0030879	9.5	CYP19A1 PGR PRL
23	response to estradiol	GO:0032355	9.26	ESR1 OXTR PRL PTGS2
24	uterus development	GO:0060065	8.8	CYP19A1 ESR1 HOXA10

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	metal ion binding	GO:0046872	9.65	CDH1 CYP19A1 ESR1 MME MMP2 MMP9
2	identical protein binding	GO:0042802	9.63	CDH1 ESR1 MMP9 PGR TRPV1 VEGFA
3	metalloendopeptidase activity	GO:0004222	9.43	MME MMP2 MMP9
4	metalloendopeptidase inhibitor activity	GO:0008191	9.32	NGF TIMP2
5	zinc ion binding	GO:0008270	9.1	ESR1 MME MMP2 MMP9 PGR TIMP2

Sources

Sources for Adenomyosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia